Measuring the impact of COVID-19 on cancer survival using an interrupted time series analysis.

Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 10 11 2023
revised: 13 12 2023
accepted: 21 12 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: aheadofprint

Résumé

Few studies have investigated the impact of the COVID-19 pandemic on cancer survival. Those that have included pandemic versus pre-pandemic comparisons that can mask differences during different periods of the pandemic such as COVID-19 waves. The objective of this study was to investigate the impact of the COVID-19 pandemic on cancer survival using an interrupted time series analysis and identify time points during the pandemic when observed survival deviated from expected survival. A retrospective population-based cohort study that included individuals diagnosed with cancer between January 2015 to September 2021 from Manitoba, Canada was performed. Interrupted time series analyses with Royston-Parmar models as well as Kaplan-Meier survival estimates and delta restricted mean survival times (RMST) at one year were used to compare survival rates for those diagnosed before and after the pandemic. Analyses were performed for eleven cancer types. Survival at one year for most cancer types was not significantly different during the pandemic compared to pre-pandemic except for individuals 50 to 74 years of age who were diagnosed with lung cancer from April to June 2021 (delta RMST: -31.6 days (95% CI: -58.3, -7.2)). With the exception of individuals diagnosed with lung cancer, the COVID-19 pandemic did not impact overall one-year survival in Manitoba. Additional research is needed to examine the impact of the pandemic on long-term cancer survival.

Sections du résumé

BACKGROUND BACKGROUND
Few studies have investigated the impact of the COVID-19 pandemic on cancer survival. Those that have included pandemic versus pre-pandemic comparisons that can mask differences during different periods of the pandemic such as COVID-19 waves. The objective of this study was to investigate the impact of the COVID-19 pandemic on cancer survival using an interrupted time series analysis and identify time points during the pandemic when observed survival deviated from expected survival.
METHODS METHODS
A retrospective population-based cohort study that included individuals diagnosed with cancer between January 2015 to September 2021 from Manitoba, Canada was performed. Interrupted time series analyses with Royston-Parmar models as well as Kaplan-Meier survival estimates and delta restricted mean survival times (RMST) at one year were used to compare survival rates for those diagnosed before and after the pandemic. Analyses were performed for eleven cancer types.
RESULTS RESULTS
Survival at one year for most cancer types was not significantly different during the pandemic compared to pre-pandemic except for individuals 50 to 74 years of age who were diagnosed with lung cancer from April to June 2021 (delta RMST: -31.6 days (95% CI: -58.3, -7.2)).
CONCLUSIONS CONCLUSIONS
With the exception of individuals diagnosed with lung cancer, the COVID-19 pandemic did not impact overall one-year survival in Manitoba. Additional research is needed to examine the impact of the pandemic on long-term cancer survival.

Identifiants

DOI: 10.1093/jncics/pkae001 PMID: 38177077
pubmed: 38177077
pii: 7511077
doi: 10.1093/jncics/pkae001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press.

Auteurs

Pascal Lambert (P)

Paul Albrechtsen Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Epidemiology and Cancer Registry, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada, R3E 0V9.

Katie Galloway (K)

Department of Epidemiology and Cancer Registry, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada, R3E 0V9.

Allison Feely (A)

Department of Epidemiology and Cancer Registry, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada, R3E 0V9.

Oliver Bucher (O)

Department of Epidemiology and Cancer Registry, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada, R3E 0V9.

Piotr Czaykowski (P)

Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 750 Bannatyne Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3E 0V9, Canada.
Department of Medical Oncology and Hematology, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada.

Pamela Hebbard (P)

Department of Surgery, Section of General Surgery, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada.

Julian O Kim (JO)

Paul Albrechtsen Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Radiology, Section of Radiation Oncology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street GA216, Winnipeg, MB R3T 2N2, Canada.
Department of Radiation Oncology, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada.

Marshall Pitz (M)

Paul Albrechtsen Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 750 Bannatyne Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3E 0V9, Canada.
Department of Medical Oncology and Hematology, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada.

Harminder Singh (H)

Paul Albrechtsen Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 750 Bannatyne Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3E 0V9, Canada.

Maclean Thiessen (M)

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3E 0V9, Canada.
Department of Medical Oncology and Hematology, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada.

Kathleen M Decker (KM)

Paul Albrechtsen Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada.
Department of Epidemiology and Cancer Registry, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada, R3E 0V9.
Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 750 Bannatyne Avenue, Winnipeg, MB, R3E 0V9, Canada.

Classifications MeSH